Orchestra BioMed Holdings, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M |
| Cost of Revenue | $190.0K | $204.0K | $186.0K | $211.0K |
| Gross Profit | $33.3M | $2.4M | $2.6M | $3.3M |
| Gross Margin | 99.4% | 92.3% | 93.3% | 94.0% |
| Operating Expenses | ||||
| Research & Development | $58.2M | $42.8M | $33.8M | $21.9M |
| SG&A Expense | $26.9M | $23.9M | $20.3M | $14.0M |
| Operating Income | $-51.8M | $-64.3M | $-51.5M | $-32.7M |
| Operating Margin | -154.7% | -2,437.5% | -1,866.2% | -924.3% |
| Interest Expense | — | $297.0K | $1.4M | $1.3M |
| Pretax Income | — | — | — | — |
| Income Tax Expense | $0 | — | — | — |
| Net Income | $-52.7M | $-61.0M | $-49.1M | $-33.6M |
| Net Margin | -157.4% | -2,313.3% | -1,779.7% | -951.3% |
| EPS (Basic) | $-1.11 | $-1.66 | $-1.48 | $-1.12 |
| EPS (Diluted) | $-1.11 | $-1.66 | $-1.48 | $-1.12 |
| Shares Outstanding (Basic) | 47.7M | 36.8M | 33.2M | 30.0M |
| Shares Outstanding (Diluted) | 47.7M | 36.8M | 33.2M | 30.0M |
| Dividends Per Share | — | — | — | — |